Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
FGEN FibroGen, Inc. monthly Stock Chart
FGEN [NASD]
FibroGen, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E114.14 EPS (ttm)0.41 Insider Own4.30% Shs Outstand83.67M Perf Week16.02%
Market Cap3.94B Forward P/E- EPS next Y-0.39 Insider Trans-9.04% Shs Float77.72M Perf Month17.94%
Income42.10M PEG- EPS next Q-0.45 Inst Own71.00% Short Float6.68% Perf Quarter13.10%
Sales356.70M P/S11.06 EPS this Y-14.30% Inst Trans-0.79% Short Ratio6.64 Perf Half Y21.81%
Book/sh6.83 P/B6.90 EPS next Y-91.30% ROA4.80% Target Price65.00 Perf Year14.03%
Cash/sh7.51 P/C6.27 EPS next 5Y- ROE7.60% 52W Range32.33 - 61.23 Perf YTD1.86%
Dividend- P/FCF- EPS past 5Y-30.80% ROI-14.00% 52W High-23.01% Beta1.81
Dividend %- Quick Ratio9.00 Sales past 5Y15.80% Gross Margin99.90% 52W Low45.80% ATR2.46
Employees461 Current Ratio9.00 Sales Q/Q14.50% Oper. Margin8.70% RSI (14)74.22 Volatility4.56% 7.79%
OptionableYes Debt/Eq0.12 EPS Q/Q-12.80% Profit Margin11.80% Rel Volume0.96 Prev Close46.78
ShortableYes LT Debt/Eq0.10 EarningsNov 11 AMC Payout0.00% Avg Volume780.99K Price47.14
Recom1.90 SMA2020.50% SMA5022.08% SMA2006.41% Volume751,051 Change0.77%
May-29-19Resumed Goldman Neutral
May-10-19Downgrade William Blair Outperform → Mkt Perform
Apr-12-19Initiated Piper Jaffray Neutral $65
Feb-11-19Resumed Stifel Buy $71
Dec-19-18Upgrade Citigroup Neutral → Buy
Aug-08-17Reiterated Stifel Buy $38 → $80
Aug-08-17Reiterated Leerink Partners Outperform $52 → $82
Jul-21-17Downgrade Goldman Buy → Neutral
Jul-11-17Initiated Jefferies Buy
Feb-11-16Upgrade Credit Suisse Neutral → Outperform $40
Jan-21-16Initiated Credit Suisse Neutral
Dec-04-15Initiated Citigroup Buy
Sep-23-15Initiated Lake Street Hold $25
Jul-29-15Initiated Citigroup Buy $37
Jul-20-15Upgrade Goldman Neutral → Buy
Dec-09-14Initiated Stifel Buy $39
Dec-09-14Initiated RBC Capital Mkts Outperform $38
Dec-02-19 07:00AM  FibroGen Announces Roxadustat Inclusion in Chinas National Reimbursement Drug List GlobeNewswire
Nov-15-19 02:20PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN ACCESSWIRE +5.75%
Nov-14-19 07:42PM  FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm Business Wire
05:24PM  Edited Transcript of FGEN earnings conference call or presentation 11-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-13-19 08:03PM  HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys, Firm Investigating Possible Securities Fraud GlobeNewswire
07:00PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. Investors Business Wire
06:19PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of FibroGen, Inc. Investors Business Wire
02:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN ACCESSWIRE
Nov-11-19 05:15PM  FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates Zacks -14.94%
05:10PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN GlobeNewswire
04:01PM  FibroGen Reports Third Quarter 2019 Financial Results GlobeNewswire
09:21AM  FibroGen (FGEN) Soars: Stock Adds 9.6% in Session Zacks
Nov-08-19 02:10PM  FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease GlobeNewswire +9.61%
01:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN ACCESSWIRE
08:14AM  The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut Benzinga
Nov-07-19 04:39PM  FibroGen Presents Phase 3 Efficacy and Safety Results for Roxadustat Versus Epoetin Alfa as Treatment of Anemia in Incident Dialysis Patients with Chronic Kidney Disease GlobeNewswire
Nov-06-19 10:41AM  Mallinckrodt (MNK) Q3 Earnings Beat, Stock Down on Sales Miss Zacks
10:36AM  Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales Zacks
09:52AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of FibroGen, Inc. (FGEN) ACCESSWIRE
08:52AM  Karyopharm (KPTI) Catches Eye: Stock Jumps 6.4% Zacks
Nov-05-19 10:18PM  HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys Now, Firm Investigating Possible Securities Fraud PR Newswire +8.00%
05:24PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN GlobeNewswire
11:17AM  Bausch (BHC) Beats on Q3 Earnings & Sales, Raises Guidance Zacks
10:42AM  Endo (ENDP) Q3 Earnings & Revenues Beat Estimates, Down Y/Y Zacks
Nov-04-19 04:38PM  FibroGen, Inc. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws GlobeNewswire -7.52%
07:00AM  FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019 GlobeNewswire
Oct-31-19 06:53AM  5 Stocks With High Net Income Ratio to Grab Now Zacks
Oct-24-19 12:17PM  Is FibroGen Inc (FGEN) Going To Burn These Hedge Funds ? Insider Monkey
08:17AM  Does Market Volatility Impact FibroGen, Inc.'s (NASDAQ:FGEN) Share Price? Simply Wall St.
Oct-23-19 07:00AM  FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer GlobeNewswire
Oct-17-19 11:20AM  Zacks.com featured highlights include: B2Gold, Burlington Stores, FibroGen, Matrix Service Company and Great Lakes Dredge & Dock Zacks
Oct-16-19 08:45AM  5 Stocks With High Net Income Ratio to Scoop Up Zacks
Oct-11-19 10:58AM  Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease (CKD) Anemia to be Presented at American Society of Nephrology Kidney Week 2019 GlobeNewswire
Oct-07-19 05:57PM  FibroGen Congratulates Dr. William G. Kaelin, Jr., Scientific Advisory Board Member, on Receipt of the 2019 Nobel Prize in Physiology or Medicine GlobeNewswire
06:41AM  UK and US scientists win Nobel Medicine Prize Financial Times
Oct-03-19 10:59AM  FibroGen Enters Oversold Territory Zacks
09:42AM  Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.2% Zacks
Sep-30-19 08:00PM  FibroGen Receives One of China Pharmaceutical Industrys Highest Awards for Clinical Innovation for Roxadustat GlobeNewswire
07:00AM  FibroGen Announces Publication in the Lancet Respiratory Medicine of Positive Pamrevlumab Efficacy and Safety Data for the Praise Phase 2 Study in Idiopathic Pulmonary Fibrosis GlobeNewswire
Sep-27-19 11:03AM  FibroGen Begins Study on Roxadustat for Chemo-Induced Anemia Zacks
Sep-26-19 11:16AM  Tyme Initiates Pivotal Stage of Pancreatic Cancer Study Zacks
09:00AM  BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors Zacks
07:00AM  FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy GlobeNewswire
Sep-25-19 08:34AM  Dova Pharmaceuticals (DOVA) Jumps: Stock Rises 8.8% Zacks
Sep-23-19 01:20PM  Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa Zacks
12:36PM  Zoetis (ZTS) Receives EC Approval for Simparica Trio in Dogs Zacks
Sep-20-19 11:54AM  FibroGen's Evrenzo Gets Nod in Japan for Anemia with CKD Zacks
03:05AM  Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients GlobeNewswire
03:00AM  Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients PR Newswire
Sep-18-19 08:13AM  Is FibroGen, Inc.'s (NASDAQ:FGEN) 7.6% ROE Worse Than Average? Simply Wall St.
Sep-13-19 11:38AM  Zacks.com featured highlights include: ACM, FibroGen, Funko, Matrix Service and PetIQ Zacks
Sep-12-19 08:40AM  What Makes Crinetics Pharmaceuticals (CRNX) a Strong Sell? Zacks
07:08AM  5 Stocks with High Net Income Ratio to Grab Now Zacks
Sep-10-19 11:46AM  Theravance Announces Positive Early Data on JAK Inhibitor Zacks
04:56AM  Endo Files BLA for CCH With the FDA for Cellulite Candidate (Revised) Zacks
Sep-09-19 09:50AM  Endo International Files BLA for Label Expansion of Xiaflex Zacks
Sep-03-19 08:35AM  Radius (RDUS) Catches Eye: Stock Jumps 6.8% Zacks -6.72%
Aug-29-19 09:50AM  Ensign Group to Spin Off Home Health & Hospice Business Zacks
Aug-27-19 09:00AM  FibroGen (FGEN) Catches Eye: Stock Jumps 7.4% Zacks
Aug-26-19 07:33PM  FibroGen CEO Thomas Neff dies suddenly as company drives toward first FDA drug approval American City Business Journals +7.38%
08:30AM  Fibrogen Announces Passing of CEO Thomas B. Neff, Scientific Innovator and Pioneering Biopharmaceutical Executive GlobeNewswire
Aug-23-19 06:15PM  Fibrogen Inc (FGEN) CEO Thomas B Neff Sold $1.8 million of Shares GuruFocus.com
Aug-22-19 06:08PM  AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China Zacks
07:18AM  The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study Benzinga
Aug-21-19 04:11PM  Roxadustat Approved in China for Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis GlobeNewswire
Aug-20-19 04:47PM  Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta Zacks
Aug-19-19 05:55PM  Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4 Zacks
Aug-15-19 10:16PM  Edited Transcript of FGEN earnings conference call or presentation 8-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
01:15AM  Fibrogen Inc (FGEN) CEO Thomas B Neff Sold $1.8 million of Shares GuruFocus.com
Aug-14-19 09:51AM  Tilray (TLRY) Catches Eye: Stock Jumps 8.4% Zacks
Aug-13-19 09:44AM  FibroGen (NASDAQ:FGEN) Has A Pretty Healthy Balance Sheet Simply Wall St.
Aug-09-19 11:07PM  FibroGen Inc (FGEN) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 08:00PM  FibroGen (FGEN) Q2 Earnings and Revenues Top Estimates Zacks
Aug-01-19 08:39PM  CORRECTION - FibroGen to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019 GlobeNewswire
07:24PM  FibroGen to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019 GlobeNewswire
Jul-30-19 10:38AM  Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline Zacks
Jul-26-19 07:15PM  Fibrogen Inc (FGEN) CEO Thomas B Neff Sold $1.9 million of Shares GuruFocus.com
Jul-24-19 06:53PM  Roxadustat China Phase 3 Trial for Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine (NEJM) GlobeNewswire
06:53PM  The New England Journal of Medicine (NEJM) Publishes Roxadustat China Phase 3 Results for the Treatment of Anemia in Chronic Kidney Disease Patients Receiving Dialysis GlobeNewswire
Jul-22-19 07:00AM  FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis GlobeNewswire
Jul-10-19 06:00AM  Shareholders Are Thrilled That The FibroGen (NASDAQ:FGEN) Share Price Increased 165% Simply Wall St.
Jun-28-19 07:00AM  FibroGen to Present Interim Phase 2 Data on Pamrevlumab in Subjects with Duchenne Muscular Dystrophy at the Parent Project Muscular Dystrophy 2019 Annual Conference GlobeNewswire
Jun-13-19 11:20AM  Heres What Hedge Funds Think About FibroGen Inc (FGEN) Insider Monkey
Jun-10-19 08:12AM  Can We See Significant Institutional Ownership On The FibroGen, Inc. (NASDAQ:FGEN) Share Register? Simply Wall St.
07:00AM  FibroGen to Present at the Goldman Sachs 40th Annual Global Healthcare Conference GlobeNewswire
Jun-05-19 05:00PM  FibroGen Appoints Suzanne Blaug to Board of Directors GlobeNewswire
May-16-19 08:54AM  Implied Volatility Surging for FibroGen (FGEN) Stock Options Zacks
May-15-19 01:00PM  FibroGen INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In FibroGen, Inc. To Contact The Firm ACCESSWIRE
May-14-19 09:07PM  Edited Transcript of FGEN earnings conference call or presentation 9-May-19 9:00pm GMT Thomson Reuters StreetEvents +6.60%
May-13-19 06:26AM  FibroGen Inc (FGEN) Q1 2019 Earnings Call Transcript Motley Fool
May-10-19 08:36PM  FibroGen INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In FibroGen, Inc. To Contact The Firm GlobeNewswire -20.32%
02:29PM  Here's Why FibroGen Fell as Much as 26.6% Today Motley Fool
12:50PM  FibroGen News: Why FGEN Stock Is Plummeting Today InvestorPlace
08:00AM  The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales Benzinga
May-09-19 08:25PM  FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:19PM  FibroGen: 1Q Earnings Snapshot Associated Press
04:44PM  FibroGen Reports First Quarter 2019 Financial Results GlobeNewswire
04:43PM  FibroGen Announces Positive Topline Results from Pooled Safety Analyses of Roxadustat Global Phase 3 Program GlobeNewswire
May-06-19 05:00PM  FibroGen to Report First Quarter 2019 Financial Results GlobeNewswire
May-02-19 02:34PM  Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss Zacks
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chung ChristineSVP, China OperationsNov 14Option Exercise21.845,625122,838145,253Nov 15 06:07 PM
Chung ChristineSVP, China OperationsNov 14Sale34.745,625195,440139,628Nov 15 06:07 PM
Chung ChristineSVP, China OperationsNov 13Option Exercise19.395,625109,069145,253Nov 15 06:07 PM
Chung ChristineSVP, China OperationsNov 13Sale34.545,625194,288139,628Nov 15 06:07 PM
Cotroneo PatSVP, Finance and CFONov 08Option Exercise2.9012,50036,250256,932Nov 12 09:15 PM
Kurkijarvi KaleviDirectorNov 07Option Exercise9.786,00058,65034,400Nov 08 06:05 PM
Kurkijarvi KaleviDirectorNov 07Sale38.276,000229,62428,400Nov 08 06:05 PM
Chung ChristineSVP, China OperationsOct 09Option Exercise19.395,625109,069145,253Oct 10 07:57 PM
Chung ChristineSVP, China OperationsOct 09Sale36.585,625205,763139,628Oct 10 07:57 PM
Chung ChristineSVP, China OperationsOct 08Option Exercise19.395,625109,069145,253Oct 10 07:57 PM
Chung ChristineSVP, China OperationsOct 08Sale36.785,625206,914139,628Oct 10 07:57 PM
Kurkijarvi KaleviDirectorOct 07Option Exercise9.786,00058,65034,400Oct 09 08:26 PM
Kurkijarvi KaleviDirectorOct 07Sale36.736,000220,38028,400Oct 09 08:26 PM
Chung ChristineSVP, China OperationsSep 20Option Exercise19.395,625109,069145,253Sep 23 06:57 PM
Chung ChristineSVP, China OperationsSep 20Sale39.875,625224,269139,628Sep 23 06:57 PM
Chung ChristineSVP, China OperationsSep 19Option Exercise19.392,12041,107145,253Sep 23 06:57 PM
Chung ChristineSVP, China OperationsSep 19Sale40.455,625227,550139,628Sep 23 06:57 PM
Cotroneo PatSVP, Finance and CFOSep 17Sale41.383,201132,457244,432Sep 18 07:42 PM
Yu K PeonyChief Medical OfficerSep 16Sale40.923,419139,905175,240Sep 18 07:45 PM
Kurkijarvi KaleviDirectorSep 09Option Exercise5.956,00035,70034,400Sep 10 08:29 PM
Kurkijarvi KaleviDirectorSep 09Sale40.956,000245,72328,400Sep 10 08:29 PM
Chung ChristineSVP, China OperationsAug 23Option Exercise19.395,625109,069157,195Aug 26 07:33 PM
Chung ChristineSVP, China OperationsAug 23Sale42.515,625239,099151,570Aug 26 07:33 PM
Chung ChristineSVP, China OperationsAug 22Option Exercise19.395,625109,069157,195Aug 26 07:33 PM
Neff Thomas BChief Executive OfficerAug 22Option Exercise2.906,83419,8192,345,012Aug 23 04:49 PM
Chung ChristineSVP, China OperationsAug 22Sale43.845,625246,583151,570Aug 26 07:33 PM
Neff Thomas BChief Executive OfficerAug 22Sale43.8718,400807,1292,326,612Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 22Sale43.771,41862,06644,238Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 21Option Exercise2.906,83419,8192,356,578Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 21Sale44.7918,400824,1362,338,178Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 21Sale44.811,41863,54145,656Aug 23 04:49 PM
Neff Thomas BChief Executive OfficerAug 13Option Exercise2.906,83419,8192,368,144Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 13Sale45.6518,400840,0062,349,744Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 13Sale45.611,41864,68047,074Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 12Option Exercise2.906,83419,8192,379,710Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 12Sale45.2418,400832,3292,361,310Aug 14 05:38 PM
Neff Thomas BChief Executive OfficerAug 12Sale45.171,41864,05648,492Aug 14 05:38 PM
Kurkijarvi KaleviDirectorAug 05Option Exercise3.506,00021,00034,400Aug 07 04:42 PM
Kurkijarvi KaleviDirectorAug 05Sale45.226,000271,32028,400Aug 07 04:42 PM
Neff Thomas BChief Executive OfficerJul 25Option Exercise2.906,83419,8192,391,276Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 25Sale46.9518,400863,8582,372,876Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 25Sale46.881,41866,47249,910Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 24Option Exercise2.906,83419,8192,402,842Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 24Sale46.5418,400856,3362,384,442Jul 26 05:31 PM
Neff Thomas BChief Executive OfficerJul 24Sale46.571,41866,03651,328Jul 26 05:31 PM
Chung ChristineSVP, China OperationsJul 11Option Exercise28.215,625158,663157,195Jul 12 04:23 PM
Neff Thomas BChief Executive OfficerJul 11Option Exercise2.906,83419,8192,414,408Jul 12 04:27 PM
Chung ChristineSVP, China OperationsJul 11Sale45.145,625253,915151,570Jul 12 04:23 PM
Neff Thomas BChief Executive OfficerJul 11Sale45.1518,400830,8362,396,008Jul 12 04:27 PM
Neff Thomas BChief Executive OfficerJul 11Sale45.091,41863,93852,746Jul 12 04:27 PM
Chung ChristineSVP, China OperationsJul 10Option Exercise29.665,625166,838157,195Jul 12 04:23 PM
Neff Thomas BChief Executive OfficerJul 10Option Exercise2.906,83419,8192,425,974Jul 12 04:27 PM
Chung ChristineSVP, China OperationsJul 10Sale44.795,625251,953151,570Jul 12 04:23 PM
Neff Thomas BChief Executive OfficerJul 10Sale44.8018,400824,3002,407,574Jul 12 04:27 PM
Neff Thomas BChief Executive OfficerJul 10Sale44.811,41863,54154,164Jul 12 04:27 PM
Kurkijarvi KaleviDirectorJul 08Option Exercise3.506,00021,00034,400Jul 10 08:18 PM
Kurkijarvi KaleviDirectorJul 08Sale42.606,000255,57028,400Jul 10 08:18 PM
Kouchakji EliasSVP, Clinical Dev, Drug SafetyJun 28Sale45.002,873129,285109,199Jul 02 08:11 PM
Neff Thomas BChief Executive OfficerJun 20Option Exercise2.906,83419,8192,437,540Jun 21 04:47 PM
Neff Thomas BChief Executive OfficerJun 20Sale44.3918,400816,8202,419,140Jun 21 04:47 PM
Neff Thomas BChief Executive OfficerJun 20Sale44.321,41862,84055,582Jun 21 04:47 PM
Chung ChristineSVP, China OperationsJun 19Option Exercise29.665,625166,838157,195Jun 20 06:15 PM
Neff Thomas BChief Executive OfficerJun 19Option Exercise2.906,83419,8192,449,106Jun 21 04:47 PM
Chung ChristineSVP, China OperationsJun 19Sale44.025,625247,613151,570Jun 20 06:15 PM
Neff Thomas BChief Executive OfficerJun 19Sale44.0218,400809,9682,430,706Jun 21 04:47 PM
Neff Thomas BChief Executive OfficerJun 19Sale43.991,41862,37857,000Jun 21 04:47 PM
Chung ChristineSVP, China OperationsJun 18Option Exercise29.662,12062,879157,195Jun 20 06:15 PM
Kouchakji EliasSVP, Clinical Dev, Drug SafetyJun 18Option Exercise14.5816,000233,200112,072Jun 20 06:19 PM
Chung ChristineSVP, China OperationsJun 18Sale44.085,625247,950151,570Jun 20 06:15 PM
Cotroneo PatSVP, Finance and CFOJun 18Sale43.123,201138,027250,777Jun 20 06:18 PM
Yu K PeonyChief Medical OfficerJun 14Sale40.963,420140,083186,976Jun 14 06:55 PM
Yu K PeonyChief Medical OfficerJun 12Option Exercise14.5810,698155,923190,396Jun 14 06:55 PM
Kurkijarvi KaleviDirectorJun 06Option Exercise2.906,00017,40034,400Jun 07 07:16 PM
Neff Thomas BChief Executive OfficerJun 06Option Exercise2.906,83419,8192,469,214Jun 07 07:38 PM
Neff Thomas BChief Executive OfficerJun 06Sale37.9418,400698,0732,450,814Jun 07 07:38 PM
Kurkijarvi KaleviDirectorJun 06Sale37.866,000227,14528,400Jun 07 07:16 PM
Neff Thomas BChief Executive OfficerJun 06Sale37.961,41853,82458,418Jun 07 07:38 PM
Neff Thomas BChief Executive OfficerJun 05Option Exercise2.906,83419,8192,480,780Jun 07 07:38 PM
Neff Thomas BChief Executive OfficerJun 05Sale38.521,41854,62159,836Jun 07 07:38 PM
Neff Thomas BChief Executive OfficerJun 05Sale38.4718,400707,9342,462,380Jun 07 07:38 PM
Schoeneck James ADirectorMay 28Option Exercise3.4114,00047,80017,700May 30 05:43 PM
Neff Thomas BChief Executive OfficerMay 23Option Exercise2.906,83419,8192,492,346May 24 07:18 PM
Neff Thomas BChief Executive OfficerMay 23Sale35.051,41849,70161,254May 24 07:18 PM
Neff Thomas BChief Executive OfficerMay 23Sale35.0118,400644,2752,473,946May 24 07:18 PM
Neff Thomas BChief Executive OfficerMay 22Option Exercise2.906,83419,8192,503,912May 24 07:18 PM
Neff Thomas BChief Executive OfficerMay 22Sale35.711,41850,63762,672May 24 07:18 PM
Neff Thomas BChief Executive OfficerMay 22Sale35.7318,400657,4322,485,512May 24 07:18 PM
Rosenkranz Roberto PedroDirectorMay 15Option Exercise16.4930,000494,73062,700May 17 04:49 PM
Neff Thomas BChief Executive OfficerMay 14Option Exercise2.906,83419,8192,515,478May 15 07:50 PM
Neff Thomas BChief Executive OfficerMay 14Sale36.901,41852,33164,090May 15 07:50 PM
Neff Thomas BChief Executive OfficerMay 14Sale36.8718,400678,4362,497,078May 15 07:50 PM
Neff Thomas BChief Executive OfficerMay 13Option Exercise2.906,83419,8192,527,044May 15 07:50 PM
Neff Thomas BChief Executive OfficerMay 13Sale35.761,41850,71265,508May 15 07:50 PM
Neff Thomas BChief Executive OfficerMay 13Sale35.8218,400659,0752,508,644May 15 07:50 PM
Kurkijarvi KaleviDirectorMay 08Option Exercise2.906,00017,40029,700May 10 06:07 PM
Chung ChristineSVP, China OperationsMay 08Option Exercise29.665,625166,838163,562May 09 09:08 PM
Chung ChristineSVP, China OperationsMay 08Sale46.315,625260,505157,937May 09 09:08 PM
Kurkijarvi KaleviDirectorMay 08Sale45.946,000275,62223,700May 10 06:07 PM
Schoeneck James ADirectorMay 07Option Exercise2.902,0005,8005,700May 09 09:00 PM
Chung ChristineSVP, China OperationsMay 07Option Exercise29.665,625166,838163,562May 09 09:08 PM
open in yahoo | open in reuters | open in google